- ISIN
- US7599161095
- CUSIP
- 759916109
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- IPO Date
- Mar 26, 1990
Highlights
- Market Cap
- $7.96B
- Enterprise Value
- $8.06B
- EPS (TTM)
- $0.73
- PE Ratio
- 192.11
- PEG Ratio
- 7.45
- Total Revenue (TTM)
- $785.10M
- Gross Profit (TTM)
- $193.96M
- EBITDA (TTM)
- $96.60M
- Year Range
- $100.99 - $175.77
- Target Price
- $152.00
- ROA (TTM)
- 1.41%
- ROE (TTM)
- 1.97%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $169.56M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RGEN Performance Chart
Repligen Corporation (RGEN) is down 13.9% since the beginning of the year. At $141 per share, RGEN is trading 19.8% below its 52-week high of $176. Investors who bought $1,000 worth of RGEN shares 5 years ago would now be looking at an investment worth $574.
Loading charts...
Compare this symbol against anything
Returns By Period
Repligen Corporation (RGEN) has returned -13.94% so far this year and 18.59% over the past 12 months. Looking at the last ten years, RGEN has achieved an annualized return of 16.86%, outperforming the S&P 500 Index benchmark, which averaged 13.26% per year.
Repligen Corporation
- 1D
- -1.80%
- 1M
- -0.98%
- 6M
- -5.60%
- YTD
- -13.94%
- 1Y
- 18.59%
- 3Y*
- -5.51%
- 5Y*
- -10.51%
- 10Y*
- 16.86%
- ALL TIME*
- 7.11%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
RGEN Monthly Returns History
Based on dividend-adjusted daily data since Mar 26, 1990, RGEN's average daily return is +0.14%, while the average monthly return is +2.24%. At this rate, an investment would double in approximately 2.6 years.
Historically, 50% of months were positive and 50% were negative. The best month was Feb 2000 with a return of +191.8%, while the worst month was Dec 1994 at -44.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.
On a daily basis, RGEN closed higher 46% of trading days. The best single day was May 4, 1998 with a return of +104.3%, while the worst single day was Jan 5, 2004 at -42.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.84% | -13.82% | -8.48% | 0.42% | 4.77% | 10.08% | 3.35% | -13.94% | |||||
| 2025 | 15.47% | -4.18% | -20.11% | 8.45% | -14.44% | 5.34% | -5.88% | 4.48% | 9.28% | 11.51% | 14.73% | -4.19% | 13.84% |
| 2024 | 5.34% | 2.42% | -5.19% | -10.72% | -9.20% | -15.45% | 32.75% | -9.81% | -1.40% | -9.78% | 12.12% | -4.38% | -19.94% |
| 2023 | 9.44% | -5.90% | -3.45% | -9.94% | 10.74% | -15.76% | 21.28% | 1.37% | -8.57% | -15.38% | 16.86% | 14.34% | 6.20% |
| 2022 | -25.11% | -0.83% | -4.38% | -16.40% | 4.60% | -1.26% | 31.38% | 2.82% | -14.71% | -2.47% | -2.00% | -5.33% | -36.07% |
| 2021 | 4.37% | 6.19% | -8.47% | 8.90% | -13.75% | 9.31% | 23.08% | 15.17% | 2.12% | 0.52% | -1.38% | -7.56% | 38.20% |
Benchmark Metrics
Repligen Corporation has an annualized alpha of 31.55%, beta of 0.84, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since March 26, 1990.
- This stock participated in 104.02% of S&P 500 Index downside but only 95.83% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 31.55%
- Beta
- 0.84
- R²
- 0.04
- Upside Capture
- 95.83%
- Downside Capture
- 104.02%
Return for Risk
Risk / Return Rank
RGEN ranks 58 for risk / return — above 58% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Repligen Corporation (RGEN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RGEN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.97 | ||
| Sortino ratioReturn per unit of downside risk | -0.99 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.25 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.51 | 2.00 | -1.49 |
| Martin ratioReturn relative to average drawdown | 1.07 | 8.49 | -7.43 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Repligen Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Repligen Corporation was 98.28%, occurring on Jul 15, 1996. Recovery took 4697 trading sessions.
The current Repligen Corporation drawdown is 56.51%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-98.28%Jul 1996 | 4y 8mo | 18y 8mo | 23y 4moOct 1991 - Mar 2015 | — |
-71.01%Sep 1990 | 3mo 15d | 11mo 27d | 1y 3moJun 1990 - Sep 1991 | — |
-68.27%May 2026 | 4y 7mo | — | 4y 10moSep 2021 - now | — |
-50.33%Feb 2016 | 7mo 5d | 1y 4mo | 1y 11moJul 2015 - Jun 2017 | — |
-32.87%Feb 2018 | 4mo 22d | 4mo 14d | 9mo 6dSep 2017 - Jun 2018 | — |
Drawdown Indicators
| RGEN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.28% | -56.78% | -41.50% |
Max Drawdown (1Y)Largest decline over 1 year | -40.28% | -9.10% | -31.18% |
Max Drawdown (3Y)Largest decline over 3 years | -50.64% | -18.90% | -31.74% |
Max Drawdown (5Y)Largest decline over 5 years | -68.27% | -25.43% | -42.84% |
Max Drawdown (10Y)Largest decline over 10 years | -68.27% | -33.92% | -34.35% |
Current DrawdownCurrent decline from peak | -56.51% | -1.58% | -54.93% |
Average DrawdownAverage peak-to-trough decline | -63.33% | -10.70% | -52.63% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.24% | 2.14% | +17.10% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Repligen Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Repligen Corporation is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for RGEN, comparing it with other companies in the Medical Instruments & Supplies industry. Currently, RGEN has a P/E ratio of 192.1. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for RGEN compared to other companies in the Medical Instruments & Supplies industry. RGEN currently has a PEG ratio of 7.4. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RGEN relative to other companies in the Medical Instruments & Supplies industry. Currently, RGEN has a P/S ratio of 10.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RGEN in comparison with other companies in the Medical Instruments & Supplies industry. Currently, RGEN has a P/B value of 3.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RGEN
Add Repligen Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RGEN